Articles tagged with Gastrointestinal Neoplasms
Researchers found a new drug, bortezomib, effective in killing gastrointestinal stromal tumor cells through two mechanisms, increasing apoptosis and suppressing KIT enzyme production. The study supports moving forward with clinical trials to assess its benefits and risks as a secondary treatment for imatinib-resistant GIST patients.
A new study published in Clinical Gastroenterology and Hepatology found that combining sigmoidoscopy and fecal immunochemical test (FIT) improves CRC detection by 10 percent. This combination is particularly useful for communities with limited colonoscopy access, as it allows for more effective screening of advanced proximal tumors.
Researchers at Duke University Medical Center have devised a way to deliver the right therapy directly to tumors using special molecules called aptamers. A tumor-targeting RNA aptamer was found to specifically bind to RNA helicase p68 in colorectal tumors, offering a promising approach for cancer treatment and therapy delivery.
A University of Florida researcher is developing a micro-endoscope that can inspect tissues beneath the surface, revealing abnormal cell groups or growth patterns before they form tumors. This technology has shown promising results in laboratory tests and could allow for earlier detection and more precise tumor removal.
Researchers found that targeting fibroblast activation protein (FAP) in tumor microenvironment significantly reduced tumor growth in mice. FAP promotes tumor growth by disrupting signaling pathways and biological processes required for tumor growth.
Fernandez-Valle's research aims to identify proteins that could deliver cancer-fighting drugs to NF2 tumors, potentially improving lifestyles and extending patients' lives. She has established nationally affiliated clinics in Florida, bringing together physicians with expertise in treating the disease.
Scientists have discovered a way to block the growth of human colon cancer cells by targeting the Hedgehog-GLI pathway, preventing tumor growth and metastasis. This breakthrough could provide a new method for treating incurable forms of colon cancer.
Scientists discovered that two cancer-promoting genes enable tumor cells to grow and survive under conditions where normal cells die. The KRAS and BRAF mutations allow cancer cells to thrive in environments with limited glucose, which may be used to develop new treatments.
New research reveals that African American patients with gastrointestinal stromal tumors (GIST) are experiencing improved survival rates, thanks to better diagnosis and surgical treatment. Prior to 2000, racial disparities in survival rates were significant, but recent improvements have closed the gap.
The AGA Foundation has awarded a $150,000 grant to Dr. Michael Choi for his research on carcinoid tumors, a type of neuroendocrine cancer. This funding will support the development of novel therapeutic approaches to improve treatment outcomes for patients with these rare and often slow-growing cancers.
A recent study by the Wildlife Conservation Society finds that cancer is a major threat to wild animal populations, with certain species at risk of extinction due to contagious cancers and pollution. The study highlights the need for increased health monitoring and resource allocation to safeguard animals and humans.
Scientists have identified a new approach to detect and treat Peutz-Jeghers syndrome, a rare inherited cancer syndrome, by exploiting tumors' weak spot in glucose metabolism. They found that targeting mTOR pathway with rapamycin can stop tumor growth, offering new treatment options.
A new study finds that individuals with low levels of the 'Celebrex gene' are resistant to Celebrex treatment for colon tumor prevention. High levels of colonic 15-PGDH expression are necessary for Celecoxib to prevent colon tumors.
Researchers at Fox Chase Cancer Center have discovered a genetic pattern that can help predict how patients with gastrointestinal stromal tumors respond to the targeted therapy imatinib mesylate. By analyzing tumor specimens, they found genes that could be suppressed to enhance the effectiveness of imatinib therapy.
A study by University of Utah researchers identified a protein called C-terminal binding protein 1 (CTBP1) as the spark that initiates colon polyp formation. This new information opens possibilities for developing future treatments to prevent tumor progression.
Researchers at Fox Chase Cancer Center identified a genetic pattern that may predict how patients respond to imatinib mesylate, and found genes that could be suppressed to enhance therapy effectiveness. The study's findings suggest potential new strategies for improving treatment outcomes in gastrointestinal stromal tumor patients.
Researchers found SIRT1 curbs cell division by speeding up the destruction of the tumor promoter c-Myc, a key finding that may aid cancer treatment. This study supports previous research suggesting SIRT1's anti-cancer effects while also identifying its role in regulating c-Myc levels.
Researchers have engineered a new version of the tumour-inhibiting protein VHL that can target hypoxic areas in tumours, reducing HIF levels and causing tumours to regress. This breakthrough has implications for treating various types of cancer, particularly those resistant to conventional therapies.
A doctoral thesis reveals that three FET genes involved in cell maturation and stress response can lead to rapid cancer development in children. The study's findings suggest that these genes' rearrangements may cause cancer cells to lose normal control mechanisms, resulting in uncontrolled growth.
Research suggests that lowering cholesterol levels can block the growth of prostate tumors and reduce cancer incidence. Ezetimibe, a cholesterol-lowering drug, has been shown to inhibit tumor angiogenesis, promoting less aggressive tumors.
Researchers have developed a model predicting recurrence in early-stage colon cancer patients and sensitivity to chemotherapy and targeted therapies. Gene expression analysis reveals specific patterns associated with higher cancer risk, enabling targeted treatments to prevent recurrences and improve survival rates.
Researchers found that patients with gastrointestinal stromal tumors (GIST) respond differently to medications depending on their unique genetic makeup. The study suggests that developing individualized treatment plans tailored to the specific mutations in each tumor could improve patient outcomes. Additionally, the analysis of Sutent'...
Researchers investigate role of GSK-3 proteins in mouse embryonic heart development and find that mice lacking GSK-3-beta exhibit hypertrophic cardiomyopathy. Additionally, studies show PTEN protein modification leads to T-ALL cell viability, while HDAC3 plays a crucial role in maintaining heart function.
The study found that GST-pi was highly expressed in neoplastic tissues and exhibited a significant increase in intensity with the grade of dysplasia. In addition, the research revealed unique ultrastructural changes in some cases characterized as mild-grade dysplasia.
Researchers at Ecole Polytechnique Fédérale de Lausanne and University of Pennsylvania School of Medicine have identified a protein called Hsp104 that dramatically reduces alpha-synuclein aggregation and dopaminergic degeneration in a rat model of Parkinson's disease. The study suggests that Hsp104 could be considered as a potential st...
Researchers at SNM's 55th Annual Meeting present a study on pre-targeting strategies that combine molecular imaging techniques with targeted therapy, offering personalized medicine to cancer patients. This approach can increase the effectiveness of therapies and minimize discomfort during treatment.
Researchers at Weill Cornell discovered that cancer stem cells without the protein CD133 can initiate metastatic disease, leading to more aggressive tumors. This finding opens up new avenues of investigation and redirects cancer research.
Researchers at Heidelberg University Hospital have discovered a new approach to immunize against certain types of cancer. They found that immune cells react strongly to modified proteins in tumor cells with DNA repair defects, which are present in around 15% of all tumors.
Excess IGF-1R protein indicates reduced responsiveness to Gleevec in gastrointestinal stromal tumors. Alternative treatments may be effective for patients with high IGF-1R levels.
A Mayo-led study found that smoking is associated with an increased risk of developing colorectal tumors lacking DNA repair proteins. Women who smoked were more likely to develop these tumors, which may be due to the loss of function in genes responsible for repairing genetic damage.
Researchers have identified a new target for cancer therapy by targeting the non-malignant cells surrounding tumors, which can stop tumor growth in mice. This approach has shown promise in reducing tumor size and slowing growth of well-established cancers after a single injection of T cells.
Researchers found that extra copies of a particular gene can repress tumor growth, while missing a copy enhances tumor growth. Mice with three copies of the gene had fewer tumors than those with two copies, while mice with one copy developed more tumors.
A study found that sunitinib increases the risk of heart problems, including heart attacks and congestive heart failure, in patients with specific tumor types. Close monitoring is recommended to manage these risks, especially in those with cardiac risk factors.
Researchers at Rice University have engineered a modified form of the anti-cancer drug imatinib, known as WBZ_4, which targets specific cancer-causing proteins without affecting normal bodily functions. This new compound shows promise in treating gastrointestinal stromal tumors (GISTs) with reduced risk of heart toxicity.
Researchers have established a direct causal connection between hypermethylation and colon tumor development in mice. Hypermethylation switches off tumor suppressor genes, boosting tumors by 60-100 percent.
Researchers at Harvard and Johns Hopkins Universities developed a new paradigm in calculating tumor development, finding that it's driven by mutations in hundreds of genes. The study suggests that individual tumors can be driven by up to 20 mutated genes, leading to better understanding and potential new treatments for cancer.
Researchers analyzed over 18,000 genes from breast and colorectal tumors to identify genetic diversity between tumor types. The study highlights the need for individualized cancer treatment targeting specific mutant genes in each patient.
Scientists identify EphB2 and EphB3 receptors as key players in limiting tumor cell growth to confined compartments. This mechanism prevents tumors from invading other tissue areas.
Researchers at Thomas Jefferson University found that colon cancer is caused by a lack of hormones that regulate intestinal epithelial cells. Hormone replacement therapy may prevent or treat the disease, shifting the focus from genetic to endocrine aspects.
A study on mucins reveals their crucial role in protecting the gut from bacterial infection. In contrast, lupus research identifies shared signaling networks active in B cells from genetically distinct mouse models. Meanwhile, a new study shows that blocking ERK1/2 activation can prevent congenital heart defects in mice with Noonan syn...
Researchers from USC identified a technique for determining a tumor's 'immune signature,' which could lead to personalized medicine and improved diagnosis. The analysis revealed that a small subset of genes is integral in explaining immunological behavior, and may be useful for matching tumors with available therapies.
A new study found that taking folic acid supplements does not reduce the risk of developing precancerous colon tumors and may even increase it. Researchers also suggest that fortification of grain-based foods with folic acid may be a contributing factor to increased risk.
New research suggests folic acid supplementation does not decrease colorectal tumor risk and may actually increase it. The study found that participants receiving folic acid had higher rates of advanced adenomas and multiple adenomas compared to those in the placebo group.
Researchers at USC have identified specific molecular markers that may help predict tumor recurrence in stage II and III colon cancer patients. The study found that genes involved in angiogenesis pathway play a critical role in tumor relapse.
Researchers have found a significant reduction in the overall colorectal tumor miss rate using advanced colonoscopy technologies, establishing a new benchmark for accurate screening and detection. High levels of C-reactive protein are also associated with increased risk of colorectal adenoma in men, but not in women.
Researchers developed a simple and accurate two-gene test that distinguishes between gastrointestinal stromal tumor (GIST) and leiomyosarcoma (LMS) with near perfect accuracy. The Top Scoring Pair analysis approach has potential for wider application in individualized diagnosis and treatment of other types of cancer.
The study reveals that PTEN-deficient intestinal stem cells can lead to changes increasing the number of stem cells and altering their position, resulting in crypt fission and budding. This process can initiate intestinal polyposis and uncontrolled tumor growth.
Researchers at City of Hope and St. Jude Children's Research Hospital developed a modified neural stem cell therapy that activates chemotherapeutic drugs primarily at tumor sites, sparing normal tissue. The approach showed promise in treating solid tumors, including neuroblastoma, with improved survival rates.
Researchers at Stanford University have found that Gleevec can block the development of disease in a mouse model of rheumatoid arthritis, providing hope for a new treatment. Imatinib inhibits the function of immune cells contributing to RA and also suppresses joint cell proliferation.
Two genes, REG1A and EXTL3, are prognostic markers for colorectal cancer recurrence. REG1A expression levels correlate with disease-free survival, while EXTL3 is a predictor of patient outcome.
Researchers developed a new method to detect oncogene mutations in human cancers, which could be used in real-time to match patients with available targeted therapies. The technique uses high-throughput mass spectrometry-based genotyping and was validated in over 1,000 tumors, representing 15 different cancer types.
Researchers develop a novel cancer vaccine delivery system using genetically modified Salmonella typhimurium that safely delivers antigens to the immune system, eliciting an immune response against cancer cells. Meanwhile, a DNA-based vaccine targeting tumor-associated fibroblasts significantly suppresses tumor growth and increases che...
A study found that colonoscopy screening in very elderly patients results in only a small gain in life expectancy, suggesting the benefit may be smaller than previously believed. The prevalence of advanced neoplasia increased with age, but the average extension of life expectancy was much lower in the elderly groups.
Studies found that exercise reduced tumour development and improved survival in mice exposed to ultraviolet B light. Exercise also decreased body fat and enhanced programmed cell death in cancer cells. The studies suggest that voluntary exercise may protect against skin and bowel cancers, but more research is needed to confirm this.
Researchers discovered that tumors producing high levels of lysyl oxidase (LOX) are more likely to spread and cause death. Blocking LOX production has promise as a new therapy for hypoxic tumors, with trials potentially starting within three years.
Current smokers and drinkers are diagnosed with colorectal cancer an average of 7.8 years younger than non-users, according to a new study. Flexible sigmoidoscopy may not detect proximal cancers as effectively as colonoscopy.
Researchers at Karolinska Institutet have identified a short peptide molecule that can vaccinate and protect against the spread of tumours from different tissues, including melanoma, colon cancer, lymphoma, and fibrosarcoma. The study points towards new possible ways of developing a treatment for advanced tumour diseases.
Researchers found that Botox injected into mouse tumors opened their cellular vasculature, allowing effective destruction of previously resistant cancer cells. This approach aims to alleviate tumor hypoxia, making them more susceptible to treatment.
A recent study published in American Journal of Roentgenology found that CT enteroclysis can detect complications like fistulas, abscesses, and tumors superior to conventional enteroclysis. This imaging method also detects minimal mucosal changes, a sign of early stage Crohn's disease, with no disadvantages.
A recent study published in The Lancet Oncology has found that keyhole surgery is a safe and effective option for treating colon cancer. Patients who underwent keyhole surgery had less blood loss, shorter hospital stays, and faster recovery times compared to those who received open surgery.